BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28776567)

  • 1. Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.
    Masciarelli S; Capuano E; Ottone T; Divona M; De Panfilis S; Banella C; Noguera NI; Picardi A; Fontemaggi G; Blandino G; Lo-Coco F; Fazi F
    Leukemia; 2018 Feb; 32(2):285-294. PubMed ID: 28776567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia.
    Lallemand-Breitenbach V; Guillemin MC; Janin A; Daniel MT; Degos L; Kogan SC; Bishop JM; de Thé H
    J Exp Med; 1999 Apr; 189(7):1043-52. PubMed ID: 10190895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
    Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
    Wang R; Zhang J; Wang S; Wang M; Ye T; Du Y; Xie X; Ye J; Sun G; Sun X
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells.
    Hu J; Sun Q; Fang W; Wang Q
    Cell Mol Biol (Noisy-le-grand); 2019 Apr; 65(4):97-100. PubMed ID: 31078158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
    Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
    Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
    Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
    Zheng PZ; Wang KK; Zhang QY; Huang QH; Du YZ; Zhang QH; Xiao DK; Shen SH; Imbeaud S; Eveno E; Zhao CJ; Chen YL; Fan HY; Waxman S; Auffray C; Jin G; Chen SJ; Chen Z; Zhang J
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7653-8. PubMed ID: 15894607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
    Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
    Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
    Nichol JN; Garnier N; Miller WH
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.
    Guillemin MC; Raffoux E; Vitoux D; Kogan S; Soilihi H; Lallemand-Breitenbach V; Zhu J; Janin A; Daniel MT; Gourmel B; Degos L; Dombret H; Lanotte M; De Thé H
    J Exp Med; 2002 Nov; 196(10):1373-80. PubMed ID: 12438428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
    Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.